On Monday, the Hong Kong stock market saw a significant decline in innovative drug concept stocks, with the sector experiencing broad-based losses. Investors' confidence was evidently under pressure. As of press time, Daiichi Pharma-B (06996) plummeted by 28.31% to HKD 2.33; Harbour BioMed-B (02142) fell by 22.91% to HKD 5.82; Hutchison China MediTech (00013) declined by 18.37% to HKD 20; Ascletis Pharma-B (01672) dropped by 18.15% to HKD 5.32; and Innovent Biologics (01801) decreased by 16.82% to HKD 41.8.
The direct trigger for this round of downturns came from the U.S. introducing new restrictions in the field of data security. According to the First Financial Daily, the U.S. National Institutes of Health (NIH) Director's Office recently announced on its official website that starting from April 4th (last Friday), it will prohibit institutions from China, Russia, Iran, and other "countries of concern" from accessing NIH's controlled data resources. This policy affects several critical platforms, including the human genotype-phenotype database (dbGaP) and the genomic data analysis cloud platform AnVIL.
These platforms have been heavily relied upon by researchers worldwide, especially in the fields of genomics and disease research, offering unique data integrity and authority. The blockade will directly impact Chinese innovative pharmaceutical companies' ability to access R&D information, consequently weakening the efficiency and depth of overseas R&D collaborations.
Additionally, despite pharmaceuticals not being affected by the recent U.S. tariffs, the overall industry chain remains shrouded in uncertainty amid the current international trade environment. Consequently, the market maintains high sensitivity to possible future policy changes. Against this backdrop, investor risk aversion led to a concentrated sell-off in the innovative drug sector.
Although the market faces short-term shocks, industry views still show long-term optimism. Some institutions believe that the recent tariff adjustments didn't involve pharmaceutical products, and the fundamental resilience of the innovative drug sector remains in the short term. Looking ahead, "going global" remains a crucial strategic direction for pharmaceutical companies, especially with incremental opportunities from Western markets continuously driving industry expansion.
In summary, the current decline in the innovative drug sector is driven by emotional adjustments due to policy news disturbances. However, the long-term logic remains unbroken, and continued attention is needed on the progress of policies and companies' ability to realize globalization.
